Individualized - The service we offer is truly ‘client’ or patient centred. It offers the ability to make treatment decisions with an emphasis on personalised therapeutics and progression towards preventative medicine. Long term patient ‘proteome records’ showing gradual disease associated changes over time will permit tracking and refinement of therapeutic responses.
Comprehensive - Our technology offers a quality result system which retains all the information available from a patient sample. The proposed approach marks a revolutionary movement away from the existing ‘one test per sample’ rationale, which is fundamentally cost and time inefficient.
Cost saving - To the health trusts and insurance firms who bear the cost of expensive, potentially long term biologic treatments.
Efficiency - in sample turn around from patient sampling to interpretation –faster than is currently possible with a range of single molecule tests. Also offers pharmaceutical companies the ability to accelerate drug development in parallel with disease biomarker discovery.
Information Quality - Of particular interest to pharmaceutical firms, proteomics directly identifies the molecules responsible for disease, whereas genomic analysis provides information only on transient ‘messenger’molecules (mRNA) or mutations within the ‘hard copy’ of our genes (DNA SNP’s etc.).